BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 20843951)

  • 1. Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men.
    Birzniece V; Sata A; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2010 Dec; 95(12):5443-8. PubMed ID: 20843951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gender difference in the neuroendocrine regulation of growth hormone axis by selective estrogen receptor modulators.
    Birzniece V; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E521-7. PubMed ID: 22319035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paracrine regulation of growth hormone secretion by estrogen in women.
    Birzniece V; Sata A; Sutanto S; Ho KK
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3771-6. PubMed ID: 20444909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor antagonism uncovers gender-dimorphic suppression of whole body fat oxidation in humans: differential effects of tamoxifen on the GH and gonadal axes.
    Birzniece V; Ho KK
    Eur J Endocrinol; 2015 Oct; 173(4):479-87. PubMed ID: 26199431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory action on GHRH-induced GH secretion of chronic tamoxifen treatment in breast cancer.
    De Marinis L; Mancini A; Izzi D; Bianchi A; Giampietro A; Fusco A; Liberale I; Rossi S; Valle D
    Clin Endocrinol (Oxf); 2000 Jun; 52(6):681-5. PubMed ID: 10848871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women.
    Gibney J; Johannsson G; Leung KC; Ho KK
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3897-903. PubMed ID: 15855258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulatory effect of raloxifene and estrogen on the metabolic action of growth hormone in hypopituitary women.
    Birzniece V; Meinhardt U; Gibney J; Johannsson G; Baxter RC; Seibel MJ; Ho KK
    J Clin Endocrinol Metab; 2010 May; 95(5):2099-106. PubMed ID: 20207825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
    Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
    Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of selective estrogen receptor modulator administration on the hypothalamic-pituitary-testicular axis in men with idiopathic oligozoospermia.
    Tsourdi E; Kourtis A; Farmakiotis D; Katsikis I; Salmas M; Panidis D
    Fertil Steril; 2009 Apr; 91(4 Suppl):1427-30. PubMed ID: 18692782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of raloxifene and estrogen on body composition in growth hormone-replaced hypopituitary women.
    Birzniece V; Meinhardt UJ; Gibney J; Johannsson G; Armstrong N; Baxter RC; Ho KK
    J Clin Endocrinol Metab; 2012 Mar; 97(3):1005-12. PubMed ID: 22170716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men.
    Doran PM; Riggs BL; Atkinson EJ; Khosla S
    J Bone Miner Res; 2001 Nov; 16(11):2118-25. PubMed ID: 11697809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double-blind, placebo-controlled crossover study.
    Juul A; Andersson AM; Pedersen SA; Jørgensen JO; Christiansen JS; Groome NP; Skakkebaek NE
    Horm Res; 1998; 49(6):269-78. PubMed ID: 9623518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males.
    Vermeulen A; Kaufman JM; Giagulli VA
    J Clin Endocrinol Metab; 1996 May; 81(5):1821-6. PubMed ID: 8626841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor blockade with tamoxifen diminishes growth hormone secretion in boys: evidence for a stimulatory role of endogenous estrogens during male adolescence.
    Metzger DL; Kerrigan JR
    J Clin Endocrinol Metab; 1994 Aug; 79(2):513-8. PubMed ID: 8045971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness.
    van den Berghe G; Weekers F; Baxter RC; Wouters P; Iranmanesh A; Bouillon R; Veldhuis JD
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3217-26. PubMed ID: 11443192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis.
    Oleksik AM; Duong T; Pliester N; Asma G; Popp-Snijders C; Lips P
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2763-8. PubMed ID: 11397884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of oxandrolone on the growth hormone and gonadal axes in boys with constitutional delay of growth and puberty.
    Malhotra A; Poon E; Tse WY; Pringle PJ; Hindmarsh PC; Brook CG
    Clin Endocrinol (Oxf); 1993 Apr; 38(4):393-8. PubMed ID: 8319371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tamoxifen and testosterone propionate in male rats: differential prevention of orchidectomy effects on sex organs, bone mass, growth, and the growth hormone-IGF-I axis.
    Fitts JM; Klein RM; Powers CA
    J Androl; 2004; 25(4):523-34. PubMed ID: 15223841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth hormone (GH) activity is associated with increased serum oestradiol and reduced anti-Müllerian hormone in healthy male volunteers treated with GH and a GH antagonist.
    Andreassen M; Frystyk J; Faber J; Kristensen LØ; Juul A
    Andrology; 2013 Jul; 1(4):595-601. PubMed ID: 23785020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.